Two New Clinical Studies Demonstrate Accuracy of Viz.ai Algorithm for Intracranial Hemorrhage Volume Measurements to Advance Timely, Critical Treatment Decisions
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data validating the accuracy and clinical utility of its AI-powered hyperdensity measurement solution for intracranial hemorrhage (ICH) management. Two independent studies highlight the ability of Viz ICH Plus to accurately and efficiently measure hemorrhage volume, quantify lateral ventricular volume, and estimate midline shift.
'Patients with ICH often require multiple scans in a short timeframe to guide treatment decisions,' said Peter Kan, MD, MPH, FRCSC, FAANS, Professor and Chair, Department of Neurosurgery, University of Texas Medical Branch. 'Manual measurements can be time-consuming and vary between providers. Viz ICH Plus enables us to assess patients more quickly, identify the most urgent cases, and determine whether intervention is needed—with greater consistency and efficiency.'
The first study published in Neurosurgery, ' Estimation of Ventricular and Intracranial Hemorrhage Volumes and Midline Shift on an External Validation Data Set Using a Convolutional Neural Network Algorithm1,' assessed the performance of Viz ICH Plus in quantifying ICH volume, bilateral lateral ventricle (BLV) volume, and midline shift (MLS). The algorithm performed well with low median absolute error in segmenting and quantifying ICH volume, BLV volume, and MLS. Viz ICH Plus achieved up to 92.3% accuracy in identifying clinically meaningful findings on scans.
The second study in the Journal of NeuroInterventional Surgery, ' Real-World Evaluation of Viz.ai's Automated Intracranial Hemorrhage Volume Calculation Tool2,' evaluated 139 patients presenting with spontaneous ICH and compared Viz.ai's automated measurements with traditional mABC/2 estimation. The study demonstrated that Viz.ai was significantly more accurate than mABC/2 (mean volume difference of 4.77±4.06 mL vs. 8.36±9.48 mL, p<0.01) and delivered results nearly 3x faster than manual methods.
'Accurate and timely volume estimation is critical for managing patients with ICH, especially in acute and intensive care settings,' said Molly Madziva Taitt, Ph.D., VP of Global Clinical Affairs at Viz.ai. 'These studies reinforce the precision, speed, and reliability of Viz ICH Plus, empowering clinicians with real-time information that can enhance decision-making and contribute to improved patient outcomes.'
With growing adoption across stroke centers and neurocritical care units, Viz.ai continues to expand its portfolio of intelligent care coordination solutions with real-world evidence and clinical rigor.
To learn more about Viz ICH Plus, visit viz.ai/hyperdensity-measurements.
1 Colasurdo, Marco MD*; Amran, Dor MSc, EE‡; Chen, Huanwen MD§; Ziv, Keren BSc, BE‡; Geron, Michal MD‡; Love, Christopher J. PhD‡; Robledo, Ariadna MD‖; O'Leary, Sean MS‖; Husain, Adam MS‖; Von Waaden, Nicholas MS‖; Garcia, Roberto MD‖; Edhayan, Gautam MD¶; Shaltoni, Hashem MD#; Memon, Muhammad Zeeshan MD#; Kan, Peter MD, MPH‖. Estimation of Ventricular and Intracranial Hemorrhage Volumes and Midline Shift on an External Validation Data Set Using a Convolutional Neural Network Algorithm. Neurosurgery ():10.1227/neu.0000000000003455, April 14, 2025.
2 Odland I, Liu KJ, Wu D, Yaeger KA, Ascanio LC, Smith C, Schuldt BR, Young T, Rossitto CP, Downes M, Vasan V, Ali M, Hardigan T, Shigematsu T, Fifi JT, Mocco J, Kellner CP. Real-world evaluation of the accuracy of the Viz.AI automated intracranial hemorrhage volume calculation tool. J Neurointerv Surg. 2025 Jan 19:jnis-2024-022564.
About Viz.ai
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250423000889/en/
CONTACT: Media Contacts
Carolyn Jones
[email protected] Yunger
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: TECHNOLOGY MEDICAL DEVICES NEUROLOGY CLINICAL TRIALS HEALTH TECHNOLOGY SOFTWARE HEALTH DATA MANAGEMENT ARTIFICIAL INTELLIGENCE
SOURCE: Viz.ai
Copyright Business Wire 2025.
PUB: 04/23/2025 09:38 AM/DISC: 04/23/2025 09:37 AM
http://www.businesswire.com/news/home/20250423000889/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Joby Expands Manufacturing Capacity in California and Ohio, Adds New Aircraft to Its Fleet
Will double production capacity in Marina, CA manufacturing site across 435,500 square feet of total space Ramping up newly renovated facility in Dayton, Ohio to manufacture and test aircraft components Leverages Toyota's manufacturing playbook to drive scale, quality and efficiency Adds new aircraft to Joby's fleet, showcasing acceleration of production SANTA CRUZ, Calif., July 15, 2025--(BUSINESS WIRE)--Joby Aviation, Inc. (NYSE:JOBY), a company developing electric air taxis for commercial passenger service, today announced the expansion of its site in Marina, California, which will double its aircraft production capacity at that location. The total site now spans approximately 435,500 square feet and will support the scale-up of commercial operations. Joby also expanded its flight test program with the addition of a new aircraft to its growing fleet. "Reimagining urban mobility takes speed, scale, and precision manufacturing. Our expanded manufacturing footprint in both California and Ohio is preparing us to do just that," said Eric Allison, Chief Product Officer. "We celebrated the opening of the new facility with the flight of our sixth aircraft, which earned airworthiness certification within a week of completion." The opening of the new manufacturing space is a big step forward as Joby gets ready to scale production and enter the market. Achieving this comes down to three key strengths: Committed to American Innovation: Drawing on top talent at its California and Ohio facilities, Joby designs, builds, and tests its aircraft in the US. Using tools like advanced data analytics and 3D printing, Joby produces components that are lighter, stronger and more flexible. With its newly expanded Marina facility, the Company plans to add hundreds of full-time jobs to support increased aircraft production. Advantage of Vertical Integration: Joby handles nearly every aspect of its aircraft and air taxi service in-house, from design and manufacturing to pilot training and operations. This vertical integration helps speed development, ensure quality, and accelerate testing and certification. It also lets Joby quickly and efficiently adapt its platform for other uses, including its hybrid hydrogen-electric propulsion testing. Close Collaboration with Toyota: Toyota engineers are deeply integrated with the Joby team, providing counsel to support Joby's work across design, manufacturing, and quality. Toyota also helps the Joby team optimize processes, streamline assembly, and offer advice related to the development of custom tooling to accelerate production. Once fully operational, the expanded Marina site is expected to be able to produce up to 24 aircraft per year, which is nearly one every other week. It will also provide key capabilities including its initial FAA production certification, conforming ground and flight testing components, pilot training simulators, and aircraft maintenance. This site strengthens Joby's broader manufacturing network, which includes three additional facilities: Santa Cruz, CA, the headquarters driving innovation and system architecture; San Carlos, CA, focused on powertrain and electronics; and Dayton, Ohio, a newly renovated facility that will manufacture and test aircraft components for Joby's Pilot Production Line. The Dayton site demonstrates the capabilities required for FAA production certification and supports the Company's plans to scale operations. Equipment installation is underway, with production ramping up to eventually build up to 500 aircraft a year at that location. Strong support from local workforce and community-based organizations, elected officials, city and county leaders, and nonprofit partners was instrumental in bringing the expanded facility to life. In 2023, Joby was awarded a $9.8 million dollar grant from the California Governor's Office of Business and Economic Development (GO-Biz) to accelerate its growth. The Company also benefited from a program through the California State Treasurer's Office, which helped reduce equipment costs by $10 million, supporting Joby's efforts to scale today and build the future of flight for tomorrow. Joby's founder and CEO JoeBen Bevirt will speak at the Reindustrialize Summit in Detroit on July 16, 2025, at 3:25 p.m. ET, highlighting the company's US-based manufacturing efforts. Follow along for updates here. About Joby Joby Aviation, Inc. (NYSE:JOBY) is a California-based transportation company developing an all-electric, vertical take-off and landing air taxi which it intends to operate as part of a fast, quiet, and convenient service in cities around the world. To learn more, visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the development and performance of our aircraft, the growth of our manufacturing capabilities, including the expected production capacity at our Marina and Dayton facilities; our regulatory outlook, progress and timing; our business plan, objectives, goals and market opportunity; plans for, and potential benefits of, our strategic partnerships; and our current expectations relating to our business, financial condition, results of operations, prospects, capital needs and growth of our operations, including the expected benefits of our vertically-integrated business model. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate", "estimate", "expect", "project", "plan", "intend", "believe", "may", "will", "should", "can have", "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: our ability to launch our air taxi service and the growth of the urban air mobility market generally; our ability to produce aircraft that meet our performance expectations in the volumes and on the timelines that we project; the competitive environment in which we operate; our future capital needs; our ability to adequately protect and enforce our intellectual property rights; our ability to effectively respond to evolving regulations and standards relating to our aircraft; our reliance on third-party suppliers and service partners; uncertainties related to our estimates of the size of the market for our service and future revenue opportunities; and other important factors discussed in the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on February 27, 2025, our Quarterly Report on Form 10-Q filed with the SEC on May 8, 2025, and in future filings and other reports we file with or furnish to the SEC. Any such forward-looking statements represent management's estimates and beliefs as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. View source version on Contacts Media Contacts: Charles Stewartpress@ Investor Contact: investors@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions
COPENHAGEN, Denmark, July 15, 2025--(BUSINESS WIRE)--A new Danish study finds no association between aluminum in childhood vaccines and 50 different health conditions, including autism, asthma, and autoimmune diseases. The findings reaffirm the safety of Denmark's childhood vaccination program. An extensive new Danish register-based study - the largest of its kind - supports the safety of the national childhood immunization program. Analyzing data from over 1 million children, the study found no increased risk of autism, asthma, or autoimmune diseases in vaccinated children. "Our results are reassuring. By analyzing data from more than one million Danish children, we found absolutely no indication that the very small amount of aluminum used in the childhood vaccination program increases the risk of 50 different health outcomes during childhood," says Anders Hviid, Head of Department at Statens Serum Institut (SSI) and principal investigator on the study. Aluminum, used as an adjuvant to enhance the immune response, has been a component in some vaccines since the 1930s. Researchers from SSI used Denmark's unique national health registers to follow children born between 1997 and 2018, investigating the associations between aluminum-containing vaccines and a total of 50 health outcomes - including asthma, allergies, autoimmune conditions, and neurodevelopmental disorders. "This is the first study of this scale and with such comprehensive analyses, and it confirms the strong safety profile of the vaccines we've used for decades in Denmark," says Anders Hviid. The results are being published at a time of heightened international debate about vaccine safety which makes the Danish study highly relevant. "In an era marked by widespread misinformation about vaccines, it is crucial to rely on solid scientific evidence. Large, population-based register studies like this one - tracking more than a million children over many years - are a bulwark against the politicization of health science which undermines public trust in vaccines. It is absolutely essential to distinguish real science from politically motivated campaigns - otherwise, it is the children who will end up paying the price," says Anders Hviid. Reference: Andersson NW, Bech Svalgaard I, Hoffmann SS, et al. Aluminum-adsorbed vaccines and chronic diseases in childhood. A nationwide cohort study. Ann Intern Med. 15 July 2025. [Epub ahead of print]. doi:10.7326/ANNALS-25-00997 Fact Box: Researchers from Statens Serum Institut (SSI) used Denmark's unique health registers to analyze data from more than 1 million Danish children born between 1997 and 2018 to investigate potential long-term health effects of aluminum-containing vaccines. The study examined 50 different conditions and found no statistical association between aluminum content in vaccines and increased risk of developing autism, autoimmune diseases, asthma, or allergic conditions such as hay fever and food allergies. The study has just been published in the prestigious medical journal Annals of Internal Statens Serum Institut (SSI) View source version on Contacts Anders Hviid, aii@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
18 minutes ago
- Business Wire
Cardlytics Introduces New Customer Insights Dashboards Within the Cardlytics Insights Portal
ATLANTA--(BUSINESS WIRE)--Cardlytics Inc. (NASDAQ: CDLX) today announced the general availability of three new dashboards within the newly revamped Cardlytics Insights Portal, a unique self-service tool that provides Cardlytics advertisers with market and customer intelligence on demand. The release includes new dashboards focused on Customer Insights – including data on brand affinity, customer migration and loyalty insights – and complement the existing Market Insights dashboards to give advertisers a more comprehensive understanding of their customers, competitors and market share opportunities. Built on Cardlytics' unparalleled network scale and visibility into $5.8 trillion of annual consumer spend, the Cardlytics Insights Portal offers differentiated value to advertisers. Not only does it help drive marketing strategies, the Portal can also play a role in informing broader business decisions, such as expanding into new markets or exploring strategic partnerships. Unlike traditional tools that rely on outdated, aggregated or modeled data, the Cardlytics Insights Portal surfaces timely and relevant insights from an extensive set of first-party purchase data whenever advertisers need them. 'As more brands turn to performance marketing channels and data-driven strategies, advertisers need reliable and timely access to insights that can help drive real outcomes,' said Rory Mitchell, Chief Business Officer at Cardlytics. 'From understanding cross-brand spending patterns to enhancing customer acquisition strategies and mitigating churn, the Cardlytics Insights Portal is setting a new standard for effective and intuitive data tools that help advertisers unlock new opportunities for growth.' "We are in the Insights Portal on a weekly basis, pulling data to share with our leadership team,' said Charlie Frankievich, VP of Guest and Culinary Insights at Shake Shack. 'The competitive share in particular is very valuable for us." Advertisers can now access six comprehensive dashboards within the Cardlytics Insights Portal: Market Summary – Explore brand and category growth across purchase channels Competitor Insights – See growth and volume trends from named competitors Geographic Insights – View regional spend and competitive comparisons on a state and designated market area (DMA) level Brand Affinity – Identify partnership opportunities to elevate brand reach and impact Customer Migration – Understand customer flows to enhance acquisition and minimize churn Loyalty Insights – Maximize customer retention strategies with visibility into valuable loyalty segmentation Learn more about the Cardlytics Insights Portal at About Cardlytics Cardlytics (NASDAQ: CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that makes commerce smarter and more rewarding for everyone. We offer a range of solutions to help advertisers and publishers grow and strengthen customer loyalty. With visibility into approximately half of all card-based transactions in the U.S. and a quarter in the U.K., Cardlytics enables advertisers to engage consumers at scale and drive incremental sales through our industry-leading card-linked offer network. Publisher partners can enhance their platforms with relevant and personalized offers that improve the shopping experience for their customers. Cardlytics also offers identity resolution capabilities through Bridg, which helps convert anonymous shoppers into known and reachable customers. Headquartered in Atlanta, Cardlytics has offices in Menlo Park, Los Angeles, Champaign, New York, and London. Learn more at or follow us on LinkedIn.
